Purchase

Recombinant Human CCL16 protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90 %, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3134


Product Information

Purity >90 %, SDS-PAGE
>90 %, SEC-HPLC
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Not tested
Expression HEK293-derived Human CCL16 protein Gln24-Gln120 (Accession# O15467) with a rabbit IgG Fc tag at the C-terminus.
GeneID 6360
Accession O15467
PredictedSize 37.2 kDa
SDS-PAGE 38-48 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Chemokine (C-C motif) ligand 16 (CCL16), also known as LEC (Liver-expressed chemokine), Monotactin-1 (MTN-1), IL-10-inducible chemokine, etc., is a small-molecule cytokine that belongs to CC chemokine family. CCL16 is expressed predominantly in the liver, thymus and spleen and has chemotactic activity towards lymphocytes and monocytes, playing a role in immunity and inflammation. (PMID: 33500726) CCL16 affects cells by binding to cell surface chemokine receptors (i.e., CCR1, CCR2, CCR5, and CCR8), and is also of interest in the tumor microenvironment, where it may influence tumor progression by modulating the tumor immune microenvironment. Studies have shown that CCL16 is a prognostic biomarker for triple-negative breast and lung cancer metastases.

References:

1. Shen W, et al. Theranostics. 2021;11(5):2297-2317. 2. Weiergräber OH, et al. Biomolecules. 2022;12(11):1588. 3. Chi HC, et al. Am J Cancer Res. 2024;14(7):3600-3613. 4. Dai Z, et al. Front Immunol. 2024;14:1299953.